Latest news with #StockUnits
Yahoo
16-05-2025
- Business
- Yahoo
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at and follow us on LinkedIn. Contacts: Media: Jenn Gordondna CommunicationsMedia@ Investors: Julian PeiHead of Investor Relations and Corporate in to access your portfolio
India.com
24-04-2025
- Business
- India.com
Narayana Murthy's Infosys approves Rs 510000000 Employee Stock Option Plans for…
India's second-largest IT firm, Infosys, has announced that its board has approved stock incentives, including Employee Stock Option Plans (ESOPs), valued at Rs 51 crore for CEO and Managing Director Salil Parekh. These incentives, which fall under categories like ESG and equity-based rewards, are part of Parekh's annual grants. According to a recent regulatory filing, the decision was based on recommendations from the Nomination and Remuneration Committee and as per the terms of Parekh's employment agreement, which had earlier received shareholder approval. Among them is 'grant of annual performance-based stock incentives (Annual Performance Equity Grant) in the form of Restricted Stock Units (RSUs) covering company's equity shares having a market value of Rs 34.75 crore as on the date of the grant under the 2015 Stock Incentive Compensation Plan (2015 plan)'. The nod also includes grant of annual performance-based stock incentives (Annual performance equity ESG grant) in the form of RSUs covering company's equity shares having a market value of Rs 2 crore as on the date of the grant under the 2015 Plan, which shall vest 12 months from the date of the grant, subject to the company's achievement of certain environment, social and governance milestones as determined by the board. It also greenlit grant of annual performance-based stock incentives (Annual performance Equity TSR grant) in the form of RSUs covering company's equity shares having a market value of Rs 5 crore as on the date of the grant under the 2015 Plan. This will vest on or after March 31, 2027 subject to certain criteria. Infosys also informed that the nod includes: 'The grant of annual performance-based stock incentives (2019 Annual Performance Equity Grant) in the form of Restricted Stock Units (RSU's) covering Company's equity shares having a market value of Rs 10 crore as on the date of the grant under the Infosys Expanded Stock Ownership Program-2019 (2019 Plan), which shall vest 12 months from the date of the grant subject to the company's achievement of certain performance criteria as laid out in the 2019 Plan.' The ESOPs will be granted with effect from May 2, 2025 and the number of RSUs will be calculated based on the market price at the close of trading on May 2, 2025, the company informed in a BSE filing on Thursday, as it released the Q4 and full year FY25 scorecard. (With Inputs From PTI)
